The field of otolaryngology is currently navigating a landscape of transformative innovation, marked by two distinct yet equally impactful avenues of progress. One path originates from the hallowed halls of scientific research, where decades of meticulous study and hypothesis testing culminate in groundbreaking therapies. The other emerges from the collective voice of patients, whose persistent advocacy and shared experiences are bringing previously overlooked conditions to the forefront of clinical consideration. Both approaches are poised to redefine patient care and reshape the practice of ear, nose, and throat medicine.
One of the most anticipated developments is the imminent FDA approval of the first gene therapy for hearing loss, signaling a potential dawn of intracochlear restorative medicine. This advancement, rooted in extensive laboratory research, promises to move beyond assistive devices towards biological correction of auditory and vestibular disorders. Simultaneously, the growing recognition and acceptance of retrograde cricopharyngeal dysfunction (RCPD), colloquially known as "can’t burp syndrome," exemplifies a paradigm shift driven by patient-led discovery and communication. Otolaryngologists are responding to these advancements with a blend of scientific curiosity, clinical enthusiasm, and a cautious optimism for the future of their specialty.
The Genesis of Intracochlear Restorative Medicine: Gene Therapy for Hearing Loss
The landscape of hearing restoration is on the cusp of a revolution with the expected U.S. Food and Drug Administration (FDA) approval of the first gene therapy specifically designed to treat hearing loss. This development, anticipated by year’s end, marks a significant milestone, ushering otolaryngology into a new era of intracochlear restorative medicine. [Following the initial report, the FDA officially approved Regeneron’s gene therapy on April 23, 2026, for the treatment of OTOF-related deafness.]
Regeneron Pharmaceuticals has been at the forefront of this innovation with its investigational therapy, DB-OTO. This dual adeno-associated virus (AAV) gene therapy is engineered to deliver a functional copy of the otoferlin (OTOF) gene to the inner hair cells within the cochlea. Clinical trials have demonstrated remarkable efficacy, particularly in children afflicted with OTOF-related deafness. In a pivotal registrational study, nine out of twelve pediatric participants who received DB-OTO exhibited clinically meaningful improvements in their hearing within 24 weeks of treatment. Notably, six of these children achieved the ability to hear soft speech without the need for assistive devices, and three attained normal hearing sensitivity, as detailed in a publication in the New England Journal of Medicine.
The profound impact of this therapy was underscored by Zheng-Yi Chen, DPhil, an associate scientist at Mass Eye and Ear’s Eaton-Peabody Laboratories and an associate professor at Harvard Medical School. Dr. Chen, who was involved in the initial trials for OTOF-related congenital deafness, described the transformative effect: "What’s truly remarkable is that suddenly, within one month after the delivery of the gene into the ears of human children, they went from completely deaf to sensing sound." He further elaborated on a preceding study published in The Lancet in 2024, where five out of six children experienced substantial hearing recovery, with auditory brainstem response (ABR) thresholds improving by an impressive 40-57 dB at speech frequencies. The long-term outcomes are equally encouraging, with the earliest treated patients now exceeding three years post-intervention, demonstrating hearing levels that approach normal and enabling them to engage in conversations and develop spoken language.
From Concept to Clinical Reality: The Decades-Long Journey
The journey of gene therapy for hearing loss, from a challenging and often underfunded concept to a tangible clinical reality, has spanned over a decade. Gwenaelle S. Géléoc, PhD, an associate professor at Harvard Medical, has been a key researcher in this field for approximately 12 years. She recalls the initial skepticism surrounding her grant proposals. "The idea was that there were therapies available—hearing aids and cochlear implants—so gene therapy just wasn’t needed," she explained. However, she and her colleagues recognized the limitations of existing assistive technologies. While cochlear implants and hearing aids are invaluable, they do not fully replicate the natural nuances of biological hearing, such as precise frequency discrimination, sound localization, or speech comprehension in noisy environments.
The pursuit of gene therapy was driven by the potential to fundamentally revolutionize the treatment of hearing loss, a condition affecting an estimated one in seven individuals in the U.S. and over 430 million globally. Congenital deafness, present in approximately 1.7 per 1,000 newborns in the U.S., is a prevalence comparable to Down syndrome and significantly higher than many rare genetic disorders. A substantial portion of these cases, over 50%, are attributed to genetic factors. While OTOF-related deafness represents a smaller fraction of congenital cases (1-3%), it was an ideal target for initial gene therapy efforts because the cochlear hair cells remain structurally intact, allowing for functional restoration.
"Gene therapy doesn’t restore structure; it restores that function of a cell that lacks a protein from a genetic defect," clarified John Greinwald, MD, professor and director of genetics in the division of pediatric otolaryngology at the Cincinnati College of Medicine. The ear’s anatomy also makes it a particularly amenable target for gene therapy. Dr. Greinwald described it as a "privileged organ," allowing for direct therapeutic delivery without systemic administration.
While the current therapy targets OTOF-related deafness, research is actively expanding to address other genetic causes of hearing loss, including GJB2-related hearing loss, Usher syndrome, and various forms of autosomal dominant deafness. Researchers are also exploring alternative delivery methods for gene therapy. Dr. Géléoc noted the limitations of AAV vectors, which have a restricted packaging capacity for larger genes. Her lab is investigating antisense oligonucleotide sequences (ASOs), short DNA strands designed to target specific gene regions, acting as a "molecular bandage" to correct deleterious mutations and restore protein expression.
Broader Implications for Clinical Practice and Newborn Screening
The advent of gene therapy for hearing loss is already influencing clinical practice, prompting an increased emphasis on genetic testing. It is anticipated that genetic testing may become a standard component of care for infants who do not pass newborn hearing screenings. Furthermore, this progress could lead to a re-evaluation of newborn hearing screening protocols. Current otoacoustic emission (OAE)-based screening methods may not always detect certain genetic forms of deafness, such as OTOF-related auditory neuropathy. Consequently, a broader implementation of automated auditory brainstem response (AABR) testing is being considered as treatment options diversify. "This may change the paradigm of how we screen newborns," Dr. Greinwald observed.
Over the next five to ten years, an acceleration in the development of new treatment options is expected as scientists target a wider array of genetic causes for hearing loss. Dr. Géléoc envisions a future where patients with hearing loss will have a comprehensive range of choices: "I think we are soon moving into a new era where patients with hearing loss will have the option of no treatment, hearing aids, cochlear implants, or gene therapy." Cochlear implantation will, however, remain a critical intervention for individuals with severe hearing loss unresponsive to gene therapy.
Encouragingly, early data suggests that the window for intervention with gene therapy may be broader than initially presumed. Clinical trials have shown measurable hearing improvements even in older children and adolescents treated beyond infancy, including participants as old as 16. While long-term language outcomes are still under scrutiny, these findings indicate that auditory and speech perception gains are achievable even in later-treated patients. Nevertheless, early detection and intervention will likely remain paramount. Dr. Greinwald foresees a future where newborns failing initial hearing screenings are promptly referred for diagnostic ABR testing, followed by early otolaryngological evaluation, genetic testing, and targeted genetic intervention by three months of age, should a treatable mutation be identified and the family opt for treatment. This represents a significant shift from assistive technologies to biological correction, truly heralding the "dawn of intracochlear restorative medicine."
RCPD: A Patient-Driven Diagnosis Emerges from the Digital Age
In parallel to the advancements in audiology, the field of laryngology is witnessing a remarkable transformation driven by patient advocacy and digital connectivity. Retrograde cricopharyngeal dysfunction (RCPD), commonly referred to as "can’t burp syndrome," has transitioned from an obscure symptom cluster to a recognized clinical entity, with effective treatment options now available for many affected individuals.
Nancy Jiang, MD, a clinical associate professor at Stanford University School of Medicine, encountered her first patient with RCPD in 2019. The patient described a condition that was entirely new to Dr. Jiang, as it was to most physicians at the time. Her subsequent research led her to a seminal 2019 paper in OTO Open by Robert Bastian, MD, titled "Inability to Belch and Associated Symptoms due to Retrograde Cricopharyngeal Dysfunction: Diagnosis and Treatment." This publication was the first to propose RCPD as a distinct clinical syndrome and to demonstrate its diagnosability and treatability. "I was extremely skeptical," Dr. Jiang admitted, "and I almost fell off my chair laughing when I read that patients were coming from Reddit."
Indeed, Dr. Bastian’s initial patient was a young man who had suffered from chronic bloating, gurgling, and an inability to burp for years, significantly impacting his quality of life. Despite consulting numerous physicians, his symptoms were consistently dismissed. "Nobody seemed to believe me that this problem even existed," the patient later shared with Undark magazine. He eventually approached Dr. Bastian after learning about his use of botulinum toxin to treat certain throat disorders, inquiring if it might offer him relief. Dr. Bastian administered the injection, and the patient’s symptoms subsequently resolved. Thrilled with the outcome, he shared his experience on Reddit, which resonated with many others experiencing similar issues. This online interaction led to a growing number of patients seeking Dr. Bastian’s expertise. By the time of his publication, he had treated 121 individuals.
The online community surrounding RCPD has since exploded. The Reddit forum "r/noburp," established in 2014, now boasts over 17,000 members. Awareness of "no burp syndrome" has also proliferated across platforms like TikTok and at otolaryngology conferences. "It quickly went viral in the field of otolaryngology because, I think, we were all seeing patients start to pop up in our clinics with questions about this," Dr. Jiang remarked. However, widespread clinical recognition remains largely confined to laryngologists.
From Symptom Cluster to Clinical Recognition: The RCPD Narrative
RCPD is characterized by a distinct constellation of symptoms, including a lifelong inability to belch, coupled with persistent gastrointestinal bloating, flatulence, and audible gurgling sounds in the chest or throat. These symptoms frequently cause significant distress and discomfort, often leading to social and professional challenges for those affected. To alleviate the internal pressure, some individuals resort to self-induced vomiting, often described as "air vomiting," by inserting a finger down their throat to trigger the gag reflex and relax the cricopharyngeal sphincter. Many patients also report an intolerance to carbonated beverages.
Historically, individuals with suspected RCPD have undergone extensive gastrointestinal evaluations, often revealing gastric air distention or a lax esophagus, but typically yielding no definitive diagnosis. Research studies utilizing high-resolution impedance manometry during a carbonated drink challenge have indicated abnormal air movement and elevated upper esophageal sphincter pressures in patients with suspected RCPD, consistent with impaired retrograde gas venting. However, manometry is not currently considered a mandatory diagnostic tool.
Currently, the diagnosis of RCPD relies heavily on a thorough clinical history and the presence of characteristic symptoms. "If the patient has ever been able to burp, it’s not RCPD," stated Tom Carroll, MD, director of the Brigham and Women’s Hospital program for Voice, Swallowing, and Upper Airway. Such individuals require further investigation.
The Unforeseen Efficacy of Botulinum Toxin and Patient-Driven Research
The injection of botulinum toxin into the cricopharyngeus muscle has proven to be a life-altering treatment for many patients, offering sustained relief that extends beyond the toxin’s pharmacological duration. The exact mechanism behind this long-lasting effect remains an area of ongoing investigation. One prevailing theory suggests that the botulinum toxin injection reduces sphincter tone, facilitating the release of trapped gas. As the toxin’s effects diminish, individuals may learn to voluntarily control the muscles and initiate belching. "I’ll be the first to tell you that I don’t fully understand what we’re doing right now. It doesn’t make any sense," admitted Joshua Schindler, MD, associate professor and division chief of laryngology at Oregon Health and Science University. He began treating RCPD patients in 2019 after reviewing Dr. Bastian’s work and found the potential benefits to outweigh the risks. His patients have reported profound improvements in their overall quality of life.
Despite the anecdotal successes, RCPD remains an emerging diagnosis with a lack of established evidence-based treatment algorithms. Botulinum toxin dosing protocols vary among practitioners, often influenced by personal experience and available patient testimonials. Doses can range from 50 to 100 units or more, leading some physicians to question the direction of patient-led treatment requests.
Approximately 70% of patients require only a single injection, typically on one side of the muscle, for sustained relief. A subsequent injection on the contralateral side may provide relief for an additional portion of patients. Recognizing the need for more robust data, Dr. Carroll and his colleagues have initiated a multicenter, prospective survey-based study to systematically assess patient symptoms before and up to a year after treatment. "We need more data," he emphasized, "We need to understand the natural course of this because currently, we meet these people once and never see a lot of them again."
The challenge of conducting placebo-controlled, randomized clinical trials for RCPD is significant in an era where successful treatments are widely publicized online. "The moment that gets done, science is very hard to accomplish because nobody wants to enter a placebo-controlled randomized trial where they have to undergo general anesthesia and they may or may not get the drug," Dr. Schindler observed.
Otolaryngology, and indeed medicine at large, faces the evolving challenge of responsibly integrating social media-driven diagnoses into clinical practice. Dr. Jiang advocates for a patient-centered approach: "These patients are suffering. Don’t dismiss them and don’t downplay their symptoms." Simultaneously, a balanced approach of curiosity and caution is essential when encountering emerging diagnoses and treatments. As highlighted in a recent JAMA Otolaryngology–Head and Neck Surgery article, "it remains essential to emphasize that online symptom recognition should prompt evaluation rather than replace it." The otolaryngology community must strive to balance openness to patient-driven discovery with the rigorous discipline of scientific validation, ensuring that both bench-originating breakthroughs and patient-bubbling insights receive the careful study and stewardship they warrant.